↓ Skip to main content

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Overview of attention for article published in BMC Cancer, September 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

patent
1 patent

Readers on

mendeley
37 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Published in
BMC Cancer, September 2019
DOI 10.1186/s12885-019-6105-3
Pubmed ID
Authors

Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 16%
Student > Ph. D. Student 3 8%
Student > Postgraduate 3 8%
Other 2 5%
Student > Bachelor 2 5%
Other 8 22%
Unknown 13 35%
Readers by discipline Count As %
Medicine and Dentistry 12 32%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Nursing and Health Professions 2 5%
Unspecified 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 4 11%
Unknown 15 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2021.
All research outputs
#7,656,056
of 23,308,124 outputs
Outputs from BMC Cancer
#2,126
of 8,441 outputs
Outputs of similar age
#134,328
of 341,355 outputs
Outputs of similar age from BMC Cancer
#41
of 161 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,441 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,355 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.